19 June 2013
Keywords: merck, co, ceo, called, before, senate, amongst
Article | 22 November 2004
Amongst all its other woes since voluntarily recalling its COX-2 inhibitor Vioxx (rofecoxib; Marketletters passim) due to clinical trial
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 November 2004
8 November 2004
18 June 2013
© 2013 thepharmaletter.com